Highest-materiality recent filing
Moderna Q1 2026 revenue $389M, GAAP net loss $(1.3)B including $0.9B litigation charge
Revenue $389M (+$281M YoY); ~80% from international; GAAP EPS $(3.40) vs $(2.52) YoY.
Moderna to pay $950M noncontingent lump sum by July 8, 2026 to resolve worldwide patent litigation over Spikevax and mRESVIA.
Moderna Q4 revenue $678M (-30% YoY); net loss $(826)M; FY2025 net loss $(2.8)B
Q4 2025 revenue $678M (-30% YoY); GAAP net loss $(826)M ($(2.11) EPS).
Moderna receives FDA Refusal-to-File for flu vaccine mRNA-1010; no impact on 2026 guidance
FDA CBER refused to review BLA for mRNA-1010 citing comparator choice, not safety/efficacy.
2025 preliminary revenue ~$1.9B ($100M above midpoint); GAAP OpEx $5.0-5.2B (improved $200M).
Moderna projects 2025 revenue $1.6-2.0B, targets up to 10% growth in 2026
2025 revenue guidance of $1.6-2.0B; cash costs beat commitments by nearly $1B.
Moderna enters $1.5B credit facility with Ares; $600M initial term loan, $900M delayed draw
$1.5B facility: $600M initial term loan and $900M delayed draw tranche available through Nov 2027/2028.
Moderna targets up to 10% revenue growth in 2026; closes $1.5B loan facility
Targets up to 10% revenue growth in 2026; expanding seasonal vaccine franchise to up to six approved products by 2028.
Moderna Q3 net loss $200M, revenue $1.0B down 45% YoY; narrows 2025 guidance
Q3 revenue $1.0B (down 45% YoY); net loss $(0.51)/share vs. EPS $0.03 in Q3 2024.
Moderna Q2 net loss $0.8B, rev $142M (-41% YoY); cuts 2025 revenue guidance high end by $300M
Q2 revenue $142M (-41% YoY); GAAP net loss $0.8B ($2.13 EPS loss).
Moderna Q1 net loss $1.0B, revenue $108M; reiterates 2025 revenue guidance $1.5-2.5B
Q1 2025 revenue $108M (down 35% YoY); GAAP net loss $(1.0)B, EPS $(2.52).
Q4 net loss $1.1B, EPS $(2.91); FY2024 revenue $3.2B falls 53%; guides 2025 rev $1.5-2.5B
Q4 revenue $1.0B (-66% YoY); GAAP net loss $1.1B vs net income $217M in Q4 2023.
2024 product sales ~$3.0-3.1B (unaudited); cash & investments ~$9.5B. Full 2024 results due Feb 14, 2025.
Moderna Q3 net income $13M, revenue $1.9B; reiterates FY product sales $3-3.5B
GAAP net income $13M ($0.03 EPS) vs net loss of $3.6B in Q3 2023; revenue $1.9B.
Expects ten product approvals through 2027, including three respiratory vaccine submissions in 2024 (next-gen COVID, flu/COVID combo, RSV for high-risk adults).
Moderna Q2 net loss $1.3B, EPS $(3.33); cuts 2024 product sales forecast to $3.0-3.5B
Revenue $241M vs $344M YoY; net product sales $184M (-37%).
Moderna Q1 revenue $167M, net loss $1.2B; reaffirms FY 2024 sales ~$4B
GAAP net loss of $1.2B and diluted EPS of $(3.07) vs. $0.19 EPS a year ago.
On September 28, 2024, the Board of Directors (the “Board”) of Moderna, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Abbas Hussain to the Board, effective October 2, 2024.
On July 19, 2024, Robert Langer and Stephen Berenson each notified Moderna, Inc. (the “Company”) of his resignation from the Board of Directors of the Company (the “Board”), including all committees on which he serves, effective August 5, 2024.
On July 19, 2024, Robert Langer and Stephen Berenson each notified Moderna, Inc. (the “Company”) of his resignation from the Board of Directors of the Company (the “Board”), including all committees on which he serves, effective August 5, 2024.
On July 19, 2024, the Board, upon the recommendation of the Nominating and Corporate Governance Committee, appointed David M. Rubenstein to the Board, effective August 5, 2024.
Max materiality 0.85 · Median 0.75 · Most common event earnings